Takeda clears key hurdle as investors back $59 billion Shire deal

Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire , creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt.